Loading...
•
Dec 31, 2019
Amicus Therapeutics Q4 2019 Earnings Report
Amicus Therapeutics' financial results for Q4 2019 and corporate updates were announced.
Key Takeaways
Amicus Therapeutics reported full-year 2019 revenue of $182.2 million, driven by Galafold sales, and anticipates Galafold revenue between $250 million and $260 million for 2020. The company is advancing its Pompe program and gene therapy pipeline, with a cash position expected to fund operations into 2022.
Galafold revenue grew to $182.2 million in 2019, exceeding guidance.
Phase 3 PROPEL trial for AT-GAA in Pompe disease exceeded enrollment.
Plans to apply for and initiate a rolling BLA for AT-GAA, completing final submission in the first half of 2021.
Cash, cash equivalents, and marketable securities totaled $452.7 million at the end of 2019.
Revenue by Segment
Forward Guidance
Amicus expects Galafold revenue between $250 million and $260 million for 2020 and non-GAAP operating expenses between $410 million and $420 million.
Positive Outlook
- On track to meet full-year 2020 revenue guidance range of $250 million to $260 million for Galafold
- Plans to apply for and initiate a Rolling Biologics License Application (BLA) for AT-GAA in 2020
- Initiate long-term follow-up of initial participants in the CLN6 Phase 1/2 study in 1H2020
- Plan to advance regulatory discussions to finalize clinical and regulatory path in CLN3
- Manufacturing advancements across portfolio
Challenges Ahead
- A reconciliation of the differences between the non-GAAP expectation and the corresponding GAAP measure is not available without unreasonable effort due to potentially high variability, complexity and low visibility as to the items that would be excluded from the GAAP measure.
- Potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...